德国拜耳公司开发的含钆造影剂Eovist(gadoxetatedisodium)于2008年7月3日获得美国食品药品管理局(FDA)批准上市[1],该药为近十年来首个在美国获得认可的器官特异性核磁共振造影剂。Eovist主要用于成人肝脏T1磁共振造影,对确诊或疑似患有肝病的患者进行检测。本品为注射剂。磁 Gadolinium-based contrast agent Eovist (gadoxetatedisodium) developed by Bayer AG in Germany was approved by the U.S. Food and Drug Administration (FDA) on July 3, 2008 [1] and is the first organ-specific organ to be approved in the United States in the last ten years Magnetic resonance imaging agent. Eovist is mainly used for T1 magnetic resonance imaging of adult liver and detects patients with confirmed or suspected liver disease. This product is injection. magnetic